Tagged with manufacturing

Indonesia Parulian Simanjuntak, Executive Director at IPMG, explains the crucial role that MNCs should play within Indonesian universal healthcare coverage (JKN) and discusses the future challenges that should be addressed to enhance the national healthcare system. Indonesia is one of the strongest pharmaceutical markets within the region. Valued at USD 5.5…

Taiwan Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing plant, which will become the largest facility of this kind in Taiwan, while the company is about to start the…

Ireland Despite a comparatively small population by European standards, Ireland’s macroeconomic indicators remain healthy, with strong GDP growth rates. Ireland is globally competitive in terms of flexibility, adaptability, human resources, culture, and economic policy. Ireland’s tax regime is also globally competitive, with favourable corporate tax rates, R&D tax credit, and an…

Taiwan Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage…

Taiwan JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The company’s chairman and CEO, PH Huang details how they have gone about utilizing their post-IPO funds to enhance the company’s…

Singapore GEA, a global leader in pharma manufacturing solutions, has recently implemented a successful reorganization to increase their country-level presence both globally and across the Asia-Pacific region with the objective to ensure an increased “customer-centric focus”. GEA is an innovative leader in automated manufacturing and processing technologies for the pharma industry…

Greece Carrying the legacy of an accomplished Greek family business, Anfarm CEO Eugenia Nicolaou speaks proudly about the company’s evolution, how Anfarm is maintaining a sustainable business model in the midst of the economic crisis, and how it is building a stronger presence in the international landscape. Anfarm is a Greek…

Taiwan Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group, and the advantages of SynCore Bio’s integration within Sinphar Group. As an introduction to our international readers, could you provide…

Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments.   What other mid-sized multinational pharmaceutical companies present in over 80…

Switzerland Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions. Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to…